point out in their work, unspecific boosting of IDE activity in order to diminish the amyloid-β (Aβ) load and tackle Alzheimer’s disease (AD) could have deleterious consequences in the insulin metabolism; vice versa, modulating IDE activity toward insulin as a therapeutic strategy for diabetes could produce an altered homeostasis of Aβ, possibly leading to AD. Here, INS is linked to diabetes mellitus.